Dalvance — HCPCS J0875 · Dalbavancin

CARECOST ESTIMATE · BILLING CHEAT SHEET

AbbVie (brand) + generic dalbavancin 500 mg/25 mL single-dose vial (only size) Single 30-min IV infusion (or 2-dose regimen) **Reviewed:** Jul 14, 2026

ASP: Q4 2026

> **#1 BILLER RULE — the rare zero-waste drug.** 1,500 mg = exactly three 500 mg vials, 1,000 mg = exactly two, 500 mg = exactly one. Nothing is discarded at standard doses — bill the full line with **JZ**, no JW split needed.

HCPCS	STANDARD DOSE	TWO-DOSE ALT.	ADMIN CPT	VIAL	PAYMENT LIMIT
J0875 1 unit = 5 mg	1,500 mg 300 units, single infusion	1,000+500 mg 1 wk apart, both JZ	96365 30-min infusion	500 mg only size → JZ (usually)	$9.439 /5mg, Q4 2026 (ASP-based, incl. 6% add-on)

SAME J-CODE, BRAND OR GENERIC

Dalbavancin has generic competition — **every NDC bills J0875** at 5 mg/unit, brand or generic. AbbVie's **Dalvance Connects** copay card has ended (last eligible date of service April 17, 2026). Brand NDC is `57970-0100-01`.

DOSING REGIMENS

REGIMEN	DOSE	VIALS	DISCARD
Single-dose (most common)	1,500 mg once	3 (1,500 mg)	**0 — JZ**
Two-dose	1,000 mg + 500 mg (1 wk later)	2 then 1	**0 on both — JZ**
Renal (CrCl<30, not HD)	1,125 mg once	3 (1,500 mg) to draw 1,125	**375 mg — JW**
Renal, two-dose	750 mg + 375 mg (1 wk later)	2 then 1	**250 mg then 125 mg — JW**

UNIT MATH & JZ/JW — WORKED EXAMPLE

```
1,500 mg → 300 units → 3 vials exact → JZ, single line, 0 discard
Payment limit: 300 × $9.439 = $2,831.70 (ASP-based, incl. 6% add-on) · pt 20% ≈ $566.34 (no copay card)
Renal 1,125 mg → 225 admin (no modifier) + 75 units JW (375 mg discard)
```

JZ and JW never appear together on the same drug, same date of service. Standard doses = JZ alone. Renal-adjusted doses = admin line no modifier + separate JW line.

ADMIN CODES

CODE	WHEN
96365	30-min infusion, once per visit (primary code)
96366	Rarely needed — infusion usually completes within 1 hr

Two-dose regimen = **two separate claims**, one week apart — don't combine into one 300-unit line.

ICD-10 — ABSSSI ANCHOR

CODE	FOR
L03.x	Cellulitis / erysipelas (most common)
L02.x	Cutaneous abscess
L08.x	Other major skin infection (ABSSSI)
B95.62	MRSA as documented organism
M86.x / T84.5x	Osteomyelitis / prosthetic-joint infection — **off-label**, document rationale

NDC (ALL 4 CURRENTLY PRICED)

MFR	NDC (11-DIGIT)	PACKAGE
AbbVie (brand)	57970-0100-01	500 mg/25 mL SDV
Generic	00480-3325-01	500 mg/25 mL SDV
Generic	65219-0120-12	500 mg/25 mL SDV
Generic	71288-0034-50	500 mg/25 mL SDV

SITE OF CARE — THE ER-AVOIDANCE PITCH

SETTING	POS	NOTES
ED (avoidance pathway)	23	Discharge-instead-of-admit for eligible ABSSSI
Infusion suite / office	11	Most common outpatient setting
HOPD	19 / 22	Facility bills drug (often 340B)

One 30-min infusion replaces weeks of vancomycin OPAT + PICC line for the right patient.

TOP DENIALS

1. **Step therapy not satisfied** — document failed/contraindicated oral or standard IV therapy
2. JZ used on a renal-adjusted dose that actually has discard (or vice versa)
3. **Expired copay card applied** — Dalvance Connects ended April 17, 2026
4. Two-dose regimen billed as one claim instead of two dated visits
5. Off-label bone/joint diagnosis without documented rationale

Dalvance Connects (AbbVie): ended — AbbVie has phased out the Dalvance Connects copay program; April 17, 2026 was the last date of service eligible for a copay claim (checked September 27, 2026). myAbbVie Assist free drug: uninsured/underinsured **AND Medicare/Medicaid meeting need criteria** (checked September 27, 2026).

Sources: FDA dalbavancin PI (DailyMed), CMS HCPCS/ASP file Q4 2026, CMS CR 13056 (JW/JZ), AMA CPT, ICD-10-CM FY2026, dalvance.com/reimbursement/patient-savings-program (confirmed active Jul 2026).